Magee-Womens Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
JAMA Cardiol. 2022 Mar 1;7(3):268-276. doi: 10.1001/jamacardio.2021.5617.
Hypertensive disorders of pregnancy are associated with future cardiovascular disease, perhaps because of subclinical cardiac dysfunction before pregnancy leading to impaired adaptation to pregnancy. Natriuretic peptides are promising biomarkers for detecting subclinical cardiac dysfunction outside of pregnancy.
To investigate whether higher concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) in early pregnancy would be associated with hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the The Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be Heart Health Study, a prospective multicenter observational study. A total of 4103 nulliparous women with complete data and no prepregnancy hypertension or diabetes who were treated at 8 clinical sites were included. Women were followed up with for 2 to 7 years after pregnancy. Data were collected from October 2010 to October 2017, and data were analyzed from August 2020 to November 2021.
NT-proBNP concentration, measured using an electrochemiluminescence immunoassay from a first-trimester blood sample.
Hypertensive disorders of pregnancy and incident hypertension (systolic blood pressure of 130 mm Hg or diastolic blood pressure of 80 mm Hg or use of antihypertensive agents) at follow-up visit.
A total of 4103 women met inclusion criteria; the mean (SD) age was 27.0 (5.6) years. Among these women, 909 (22.2%) had an adverse pregnancy outcome, and 817 (19.9%) had hypertension at the follow-up visit. Higher NT-proBNP concentrations were associated with a lower risk of hypertensive disorders of pregnancy (adjusted odds ratio per doubling, 0.81; 95% CI, 0.73-0.91), which persisted after adjustment for age, self-reported race and ethnicity, early-pregnancy body mass index, smoking, and aspirin use. Similarly, higher NT-proBNP concentration in early pregnancy was also associated with a lower risk of incident hypertension 2 to 7 years after delivery (adjusted odds ratio per doubling, 0.84; 95% CI, 0.77-0.93), an association that persisted after controlling for confounders, including hypertensive disorders of pregnancy.
In this cohort study, higher NT-proBNP concentrations in early pregnancy were associated with a lower risk of hypertensive disorders of pregnancy and hypertension 2 to 7 years post partum. These findings suggest that normal early-pregnancy cardiovascular physiology, as assessed by NT-proBNP concentration, may provide biologic insights into both pregnancy outcome and cardiovascular disease risk.
妊娠高血压疾病与未来的心血管疾病有关,这可能是因为妊娠前的亚临床心脏功能障碍导致对妊娠的适应不良。利钠肽是检测妊娠外亚临床心脏功能障碍的有前途的生物标志物。
研究妊娠早期 N 端脑利钠肽前体(NT-proBNP)浓度升高是否与妊娠高血压疾病和产后 2 至 7 年高血压有关。
设计、地点和参与者:这项队列研究使用了来自无妊娠结局研究:监测母亲心脏健康研究的数据集,这是一项前瞻性多中心观察性研究。共有 4103 名无妊娠高血压或糖尿病且完整数据的初产妇纳入研究,她们在 8 个临床地点接受治疗。对这些女性进行了 2 至 7 年的随访。数据收集于 2010 年 10 月至 2017 年 10 月,分析数据的时间为 2020 年 8 月至 2021 年 11 月。
使用来自妊娠早期血液样本的电化学发光免疫分析法测量 NT-proBNP 浓度。
妊娠高血压疾病和随访时发生的高血压(收缩压 130mmHg 或舒张压 80mmHg 或使用降压药物)。
共有 4103 名女性符合纳入标准;平均(SD)年龄为 27.0(5.6)岁。这些女性中,909 名(22.2%)有不良妊娠结局,817 名(19.9%)在随访时患有高血压。NT-proBNP 浓度升高与妊娠高血压疾病风险降低相关(每增加一倍的调整后比值比,0.81;95%CI,0.73-0.91),这种相关性在调整年龄、自我报告的种族和民族、孕早期体重指数、吸烟和使用阿司匹林后仍然存在。同样,妊娠早期 NT-proBNP 浓度升高也与产后 2 至 7 年发生高血压的风险降低相关(每增加一倍的调整后比值比,0.84;95%CI,0.77-0.93),这种相关性在控制包括妊娠高血压疾病在内的混杂因素后仍然存在。
在这项队列研究中,妊娠早期 NT-proBNP 浓度升高与妊娠高血压疾病和产后 2 至 7 年高血压风险降低相关。这些发现表明,NT-proBNP 浓度评估的正常妊娠早期心血管生理学可能为妊娠结局和心血管疾病风险提供生物学见解。